As of the latest trading close, MNKD, a Healthcare sector stock, is trading 1.57% below its 52-week high but remains 134.70% above its 52-week low. The Average True Range (ATR) (14 days) of 0.25 ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Leerink Partners has recently resumed MannKind Corp (MNKD) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on June 13, 2024, Rodman & Renshaw had initiated ...

In a report released on November 7, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind (MNKD – Research Report), ...

MannKind Corp (MNKD) reports a 37% revenue increase, driven by Tyvaso DPI and Afrezza, while navigating market challenges and ...

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have received a consensus recommendation of “Buy” from the seven ...

MannKind (MNKD) reported $70.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 36.7%. EPS of $0.04 for the same period compares to $0.02 a year ago.

International Assets Investment Management LLC boosted its stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 511 ...

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 9.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI, or MNKD-201, for pulmonary fibrotic ...